Technology
Health
Biotechnology

Cellectar Biosciences

$2.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-6.10%) Today
+$0.01 (0.43%) After Hours

Why Robinhood?

You can buy or sell CLRB and other stocks, options, ETFs, and crypto commission-free!

About

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. Read More The company was founded in June,1996 and is headquartered in Florham Park, NJ.

Employees
7
Headquarters
Florham Park, New Jersey
Founded
1996
Market Cap
10.93M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
164.44K
High Today
$2.46
Low Today
$2.26
Open Price
$2.44
Volume
88.95K
52 Week High
$12.90
52 Week Low
$1.22

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
2018 IPO
US
North America

News

StreetInsiderMar 19

Cellectar Biosciences (CLRB) Announces FDA Exemption to Import Alert for CLR 131 in Pediatric and Adolescent Patients

Cellectar Biosciences, Inc. (NASDAQ: CLRB) today announced that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC) for the use of CLR 131 in connection with the company’s pediatric IND. This exemption will allow Cellectar to immediately begin enrolling patients in its Phase 1 pediatric study for the treatment of select relapsed or refractory solid tumors including neuroblastoma, lymphomas and malign...

4
Simply Wall StMar 13

Does Market Volatility Impact Cellectar Biosciences, Inc.’s (NASDAQ:CLRB) Share Price?

If you’re interested in Cellectar Biosciences, Inc. (NASDAQ:CLRB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The other type, which cannot be diversified away, is the ...

134
Markets InsiderFeb 26

Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

FLORHAM PARK, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2018, and provided a corporate update. Fourth Quarter and Recent Corporate Highlights Announced additional positive top-line results from the relapse refractory multiple myeloma cohort in its ongoing Pha...

204

Earnings

-$2.10
-$1.38
-$0.66
$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.